share_log

T2 Biosystems | 4: Statement of changes in beneficial ownership of securities-Officer Giffin Brett A.

SEC announcement ·  Feb 20 16:06
Summary by Moomoo AI
Brett A. Giffin, the Chief Commercial Officer of T2 Biosystems, Inc. (TTOO), executed a transaction on February 20, 2024, involving the acquisition of 13 shares of common stock. The transaction was classified as an exercise or conversion of derivative security, as per the transaction code 'M'. Following this transaction, Giffin's direct holdings in the company increased to a total of 77 shares of common stock. The transaction reflects a continued investment by the executive in the company, signaling confidence in T2 Biosystems' prospects.
Brett A. Giffin, the Chief Commercial Officer of T2 Biosystems, Inc. (TTOO), executed a transaction on February 20, 2024, involving the acquisition of 13 shares of common stock. The transaction was classified as an exercise or conversion of derivative security, as per the transaction code 'M'. Following this transaction, Giffin's direct holdings in the company increased to a total of 77 shares of common stock. The transaction reflects a continued investment by the executive in the company, signaling confidence in T2 Biosystems' prospects.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more